Wellfully (ASX:WFLOA) OCF Margin %: 34.15% (As of Dec. 2023)


What is Wellfully OCF Margin %?

Wellfully ASX:WFLOA OCF Margin % is 34.15% as of Dec. 2023. The stock has 7 warning signs investors should review.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Wellfully's Cash Flow from Operations for the six months ended in Dec. 2023 was A$0.03 Mil. Wellfully's Revenue for the six months ended in Dec. 2023 was A$0.08 Mil. Therefore, Wellfully's OCF Margin % for the quarter that ended in Dec. 2023 was 34.15%.

As of today, Wellfully's current OCF Yield % is 0.00%.

The historical rank and industry rank for Wellfully's OCF Margin % or its related term are showing as below:


ASX:WFLOA's OCF Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 4.755
* Ranked among companies with meaningful OCF Margin % only.

Wellfully OCF Margin % Related Terms

Wellfully OCF Margin % Historical Data

* Premium members only.

The historical data trend for Wellfully's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wellfully OCF Margin % Chart

Wellfully Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -150.20 -3,995.52 -1,307.04 -393.18 -162.00

Wellfully Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -347.76 -460.42 -866.43 -3.49 34.15

Wellfully OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Wellfully's OCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-2.443/1.508
=-162.00 %

Wellfully's OCF Margin for the quarter that ended in Dec. 2023 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=0.028/0.082
=34.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 34.15% mean?
Wellfully (ASX:WFLOA) has a OCF Margin % of 34.15% as of Dec. 2023. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Wellfully and its competitors.
Is Wellfully's OCF Margin % too high?
Wellfully's current OCF Margin % is 34.15%. The Medical Diagnostics & Research industry median OCF Margin % is 4.76. Wellfully's value of 34.15% is 618.2% above this industry median.
How does Wellfully's OCF Margin % compare to TMO and DHR?
Wellfully's OCF Margin % of 34.15% can be compared against companies in the Medical Diagnostics & Research industry. The industry median OCF Margin % is 4.76. Wellfully's value of 34.15% is 618.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.76, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wellfully's current OCF Margin % of 34.15% is 618.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Wellfully and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wellfully's current OCF Margin % is 34.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wellfully stock overvalued right now?
Wellfully (ASX:WFLOA) has a current OCF Margin % of 34.15%. The current OCF Margin % is 34.15% and 618.2% above the Medical Diagnostics & Research industry median of 4.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Wellfully (ASX:WFLOA), the current OCF Margin % is 34.15% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wellfully Business Description

Address 284 Oxford Street, Ground Floor, Leederville, WA, AUS, 6007
Wellfully Ltd is engaged in the research and development of Dermaportation and ETP transdermal drug delivery technologies. The company operates in segments namely the development of the dermaportation drug delivery technology and Devices segments. Geographically, it derives a majority of its revenue from Europe and also has a presence in Japan. It serves the Pharmaceutical; Cosmetics Skincare and Consumer Healthcare industries.